|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the translocations t(4;11), t(6;11), t(9;11), t(X;11), and t(10;11) in other leukemias were found to disrupt the same region of chromosome 11q23, although an exception was found in one t(6;11) translocation for which the breakpoint was distal to the YAC.
|
1391936 |
1992 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Development of T-cell leukaemia in an ataxia telangiectasia patient following clonal selection in t(X;14)-containing lymphocytes.
|
1518308 |
1992 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell clones carrying an inv(14), tandem t(14;14) and t(X;14) can be present in AT for long periods of time without evolving into leukemia.
|
1913594 |
1991 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One-third of the leukemia cells expressed a mature suppressor/cytotoxic T cell phenotype (T3+ T4- T6- T8+ T10-), two-thirds demonstrated additional helper/inducer T cell-associated antigens (T3+ T4+ T6- T8+ T10-), and a small fraction reacted with a natural killer (NK) cell-specific monoclonal antibody (Leu 11+).
|
2942200 |
1986 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that clonal karyotypic abnormalities are frequently found in the stem cell-like (CD34+/CD38-) and more mature (CD34+/CD38+) populations of patients with AML, irrespective of the phenotype of the bulk population of leukemic blasts and of the primary or secondary character of the leukemia.
|
7579382 |
1995 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Its potential role in leukemogenesis is supported by its overexpression in leukemia with t(X;14), but its function remains unknown.
|
7970717 |
1994 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
People with ataxia telangiectasia (AT) are at a higher than normal risk of T cell leukaemia and often have either non-malignant or malignant T cells with chromosomal abnormalities, typically t(14;14), inversion 14 or more rarely t(X;14).
|
8036021 |
1994 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the leukemia with inv(3)(q21q26) represents a new cytogenetic-clinicopathologic subtype, characterized by 1) abnormal megakaryopoiesis and multiple hematopoietic lineage involvement; 2) an antecedent MDS; 3) poor response to conventional chemotherapy; and 4) expression of CD7, CD34, CD38, HLA-DR, CD13, and CD33 antigens.
|
9209472 |
1997 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we characterize two additional t(X;14) bearing leukemias allowing this analysis.
|
9315101 |
1997 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11)(p13;q14-21) is a non-random translocation that occurs primarily in T cell acute lymphoblastic leukemias (T-ALL), but has also been observed in leukemias and lymphomas of diverse lineages.
|
9737689 |
1998 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, CD34+/CD38- leukemia precursors, in contrast with CD38+ precursors, failed, under appropriate conditions, to differentiate into dendritic cells, a central step for antigen recognition.
|
10969785 |
2000 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11)(p13;q14-21) is a non-random translocation described in acute lymphoblastic and myeloid leukaemias.
|
11417476 |
2001 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To clarify the clinical features of t(10;11)-leukemias, we investigated 6 samples from acute leukemia patients with t(10;11) and MLL rearrangement and detected MLL-AF10 chimeric transcripts in 5 samples and MLL-ABI1 in one.
|
11477655 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
No statistically significant differences were observed at diagnosis between patients with the CC genotype and homozygous or heterozygous T allele carriers with respect to age at disease onset, sex distribution, proportion of patients with CD38+ leukaemia or patients in Binet stage A, blood cell counts, degree of bone marrow infiltration or serum levels of lactate dehydrogenase, thymidine kinase or beta2-microglobulin.
|
14692527 |
2003 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels.
|
16329108 |
2006 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
|
16642047 |
2006 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 is a powerful disease marker for human leukemias and myelomas, is directly involved in the pathogenesis and outcome of human immunodeficiency virus infection and chronic lymphocytic leukemia, and controls insulin release and the development of diabetes.
|
18626062 |
2008 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
|
19147788 |
2009 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(10;11) translocation results in a CALM-AF10 fusion gene in a subset of leukemia patients.
|
20007546 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD34(+)CD38(-)CD19(+), CD34(+)38(+)CD19(+), and CD34(-)CD38(+)CD19(+) fractions could self-renew and transfer the leukemia, whereas the CD34(-)CD38(+)CD19(+) fraction did not stably propagate in NOD/SCID mice.
|
20028384 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
|
21330473 |
2011 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
|
21393419 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, peptide inhibition of BCL6 in human CML cells compromises colony formation and leukemia initiation in transplant recipients and selectively eradicates CD34(+) CD38(-) LICs in patient-derived CML samples.
|
21911423 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relapse of acute myeloid leukemia (AML) is thought to reflect the failure of current therapies to adequately target leukemia stem cells (LSCs), the rare, resistant cells presumed responsible for maintenance of the leukemia and typically enriched in the CD34(+)CD38(-) cell population.
|
22262762 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed that CD34⁺/CD38⁻ acute myelogenous leukemia (AML) cells, which contain leukemia stem cells, expressed a greater amount of the phosphorylated forms of JAK2 and STAT5 (p-JAK2 and p-STAT5) than their CD34⁺/CD38⁺ counterparts.
|
23564444 |
2013 |